<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910425</url>
  </required_header>
  <id_info>
    <org_study_id>NU 19U05</org_study_id>
    <secondary_id>NCI-2021-05593</secondary_id>
    <secondary_id>STU00212326</secondary_id>
    <secondary_id>NU 19U05</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT04910425</nct_id>
  </id_info>
  <brief_title>PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer</brief_title>
  <official_title>Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic&#xD;
      resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater&#xD;
      than or equal to 2 ng/mL. 18F-DCFPyl is a radioactive injectable imaging agent made of a&#xD;
      prostate specific membrane antigen (PSMA) that attaches to tumor cells, which makes it useful&#xD;
      for the diagnosis of prostate cancer. A PET scan is an imaging tool that may help find the&#xD;
      location of cancer, by using a radioactive drug and a computer to create images of how organs&#xD;
      and tissues in the body are functioning. A mp-MRI is used to help determine the extent of a&#xD;
      patient's cancer. A MRI scan uses strong magnets and computers to create detailed images of&#xD;
      the soft tissue in the body. This trial aims to compare PET scans to prostate specific mp-MRI&#xD;
      to evaluate prostate cancer severity in men with a positive screen for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Compare the fluorine F 18 DCFPyL (18-F-DCFPyL) PET to multiparametric magnetic resonance&#xD;
      imaging (mpMRI) for the diagnosis of clinically significant prostate cancer in biopsy naive&#xD;
      men as defined by Gleason score &gt;= 3+4 (International Society of Urological Pathology [ISUP]&#xD;
      group &gt;= 2).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Compare the combined 18-F-DCFPyL PET and mpMRI to mpMRI alone for the diagnosis of&#xD;
      clinically significant prostate cancer in biopsy naive men as defined by Gleason score &gt;= 3+4&#xD;
      (ISUP group &gt;= 2).&#xD;
&#xD;
      II. Estimate the sensitivities and specificities of combined 18-F-DCFPyL PET/mpMRI, mpMRI&#xD;
      alone, 18-F-DCFPyL PET alone, and prostate health index (PHI) alone for the diagnosis of&#xD;
      clinically significant prostate cancer.&#xD;
&#xD;
      III. Estimate the accuracy of PET alone for the diagnosis of clinically significant prostate&#xD;
      cancer in biopsy naïve men as defined by Gleason score &gt;= 3+4 (ISUP group &gt;=2).&#xD;
&#xD;
      IV. Compare the accuracy of PET to prostate health index (PHI) for the diagnosis of&#xD;
      clinically significant prostate cancer in biopsy naive men as defined by Gleason score &gt;= 3+4&#xD;
      (ISUP group &gt;= 2).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive fluorine F 18 DCFPyL intravenously (IV) and undergo PET/MRI. Patients also&#xD;
      receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and&#xD;
      undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo&#xD;
      transrectal ultrasound (TRUS) guided prostate biopsy per standard of care.&#xD;
&#xD;
      After completion of study intervention, patients are followed up within 24 hours, and then at&#xD;
      30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 17, 2021</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18-F-DCFPyL positron emission tomography (PET) vs multiparametric magnetic resonance imaging (mpMRI) for the diagnosis of clinically significant prostate cancer in biopsy naïve men.</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be compared to multiparametric magnetic resonance imaging (mpMRI) for the diagnosis of clinically significant prostate cancer in biopsy naive men as defined by Gleason score &gt;= 3+4 (International Society of Urological Pathology [ISUP] group &gt;=2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of combined PET-mpMRI to mpMRI</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be estimated and compared to mpMRI alone for the diagnosis of clinically significant prostate cancer in biopsy naive men as defined by Gleason score &gt;= 3+4 (ISUP group &gt;= 2).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluorine F 18 DCFPyL IV and undergo PET/MRI. Patients also receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo TRUS guided prostate biopsy per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorine F 18 DCFPyL</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>18F-DCFPyL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobenate Dimeglumine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>Gd-BOPTA</other_name>
    <other_name>MultiHance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>BAY86-4875</other_name>
    <other_name>Gadavist</other_name>
    <other_name>Gadograf</other_name>
    <other_name>Gadovist</other_name>
    <other_name>Protovis</other_name>
    <other_name>ZK 135079</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multiparametric Magnetic Resonance Imaging</intervention_name>
    <description>Undergo mpMRI</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>MP-MRI</other_name>
    <other_name>mpMRI</other_name>
    <other_name>Multi-parametric MRI</other_name>
    <other_name>Multiparametric MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal Ultrasonography Guided Biopsy</intervention_name>
    <description>Undergo TRUS-guided biopsy</description>
    <arm_group_label>Diagnostic (18F-DCFPyL PET/MRI, mpMRI)</arm_group_label>
    <other_name>TRUS Biopsy</other_name>
    <other_name>TRUS-Guided Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a positive screen for prostate cancer as confirmed by a prostate&#xD;
             specific antigen (PSA) &gt;= 2 ng/ml&#xD;
&#xD;
          -  Patients must elect to elect to undergo PHI blood test and TRUS-guided elect to&#xD;
             undergo PHI blood test and TRUS-guided biopsy as part of routine clinical care&#xD;
&#xD;
          -  Patients must be age &gt;= 18 years&#xD;
&#xD;
          -  Patients must agree to use adequate contraception (e.g. Barrier method of birth&#xD;
             control; abstinence) for 24 hours following completion of imaging&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent prior to registration on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had a prior biopsy for prostate cancer&#xD;
&#xD;
          -  Patients who have contraindications to MRI (i.e. pacemakers, aneurysm clips or shaped&#xD;
             fragments) are not eligible&#xD;
&#xD;
          -  Patients receiving any other treatments or investigational agents are not eligible&#xD;
&#xD;
          -  Patients with a glomerular filtration rate (GFR) &lt; 30mL/min are ineligible to receive&#xD;
             intravenous contrast per standard magnetic resonance (MR) exclusion criteria&#xD;
&#xD;
          -  Patients administered a radioisotope &lt; 5 physical half-lives prior to the date of&#xD;
             study PET/MRI&#xD;
&#xD;
          -  Patients administered IV X-ray contrast medium &lt; 120 hours prior to the date of study&#xD;
             PET/MRI&#xD;
&#xD;
          -  Patients who report taking multivitamins on the day of study PET/MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward M Schaeffer, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>(312) 695-1301</phone>
    <email>cancertrials@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Edward M. Schaeffer</last_name>
      <phone>312-694-9001</phone>
      <email>e-schaeffer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Edward M. Schaeffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

